DEVICARE RAISES €1.6M, THE LARGEST HEALTHCARE CROWDFUNDING ROUND IN SPAIN

19/07/2019
Diego Gutiérrez
DEVICARE RAISES €1.6M, THE LARGEST HEALTHCARE CROWDFUNDING ROUND IN SPAIN

Devicare, part of the healthcare sector, has developed an innovative solution for the treatment of kidney stones. We analyse its recent €1.6m round as well as other relevant corporate transactions in the sector.

 DEVICARE health sector

DEVICARE

Devicare is a Spanish company specialising in urological therapeutic solutions. It currently has a staff of 25 people, a scientific and clinical advisory board and strategic alliances with leading organisations.

It has recently developed a solution for the non-surgical treatment of renal lithiasis or kidney stones, called Lit-Control, with commercial agreements in 30 countries with different pharmaceutical companies. This medical solution consists of three nutraceuticals to modulate the pH of the patient's urine and inhibit the growth of different types of crystals, and a medical device to monitor the urinary pH.

It has recently closed the largest round of crowdfunding health care in Spain of more than 1,6M€ through Capital Cell to accelerate its growth, primarily the entry into new markets and finalise the development of a app for Lit-Control.

Other relevant operations in the sector include:

ALGENEX

This biotech company has innovated in recombinant molecule production technologies. In particular, it has invented and patented a robotic production platform that does not require complex and costly bioreactors. In this way, Algenex has succeeded in simplifying the process, improving productivity and reducing the costs associated with setting up a biologics factory by up to 95%.

With the latest round of 4M€ The new company has closed and the appointment of top professionals will seek to expand its product and achieve a wider reach through its commercial roll-out.

SOM BIOTECH

It is a company specialising in the repositioning of drugs to treat rare diseases of the nervous system. It currently has a theoretical company value of more than 200 million euros, guaranteed by independent experts.

Som Biotech has managed to raise 7M€ in a round of funding, which will go towards finalising the project they are working on to test the efficacy and safety of an innovative treatment for the choreic movements associated with Huntington's disease.

CUBIQ FOODS

Cubiq Foods develops and produces cultured fat from animal cells that are tailored to the needs of industrial customers. It has a unique technology to produce healthy fats with a wealth of applications that address the need to find an affordable alternative to questionable ingredients such as palm oil.

Los 12M€ raised in its latest round will be used to continue its expansion by setting up an R&D laboratory, boosting production capacity and opening new production plants.

SANIFIT

Sanifit is a biopharmaceutical company focused on treatments for progressive vascular calcification disorders. The company was founded in 2007 as a spin-off from the University of the Balearic Islands.

Caixa Capital Risk has led its latest round of financing closed at 55M€. This funding will help accelerate clinical development of the drug, which could be a cornerstone in the treatment of cardiovascular diseases related to calcification.

Lastest news

The State of Technology M&A in Spain | October 2026 analysis

En octubre de 2026 hubo 37 operaciones de M&A tecnológico en España: 16 fueron adquisiciones corporativas, inversiones de private equity, fusiones o tomas de participación, y 21 fueron rondas de venture capital. El 62,2% de las operaciones (23 de 37) fueron...

Webinar | How much does your business depend on you?

IMPORTANT INFORMATION: Registration for and participation in the webinars are completely anonymous to third parties. If, for a month, you were unable to have a say in important decisions, what would happen in your company? Your company can grow, be profitable and have good...

Notable technology M&A deals in Spain | September 2026 Analysis

Technology M&A in Spain totalled 61 identified transactions by the end of September 2026, the highest figure in the monthly series we have been publishing since May. Of these, 41 were acquisitions, private equity investments, asset purchases, joint ventures or takeovers...

Baker Tilly advises Invelon on the acquisition of byAR

In September 2026, Invelon, a Spanish technology company specialising in virtual, augmented and mixed reality, completed the acquisition of a majority stake in byAR, a Portuguese company specialising in museum exhibitions and the development of spaces...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

    On which topic would you like to receive information?